Clinical Trial Search

Primary: Change From Baseline in Mean Ambulatory Diastolic Blood Pressure (DBP) in the Last 4 Hours After 12-week Treatment — 85.28; 85.68; -4.45; -3.39 mmHg

Primary: Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to 24 h at Steady State — 1182.084; 1110.095; 1070.909 ng*h/mL

Primary: Percentage Change From Baseline of Thigh Muscle Volume (TMV) by MRI Scan at Week 8 — 2.0; 0.65 Percentage Change of TMV

Primary: Ranked Adjusted 2-Component Composite Variable Score Based on Change From Baseline to Week 53 — 69.81; 50.86 sum of the ranked scores — p=0.0049

Primary: Percentage Change From the Combined Baseline in the Generalized Tonic-clonic Seizure Frequency Per Week Over the 28-week Treatment Period (Dose Adjustment + Evaluation…

Primary: The Antiretroviral Activity of Etravirine 400 mg Given Once Daily, With Fixed-dose Truvada Once Daily, Among Treatment-naïve HIV-1 Infected Adults as Measured by the…

Primary: Number of Subjects Who Completed Desensitization Protocol — 6; 12 participants

Primary: Sensitivity — 0.28; 0.72; 0.78; 1.33 # vascular sites detected per patient

Primary: Change in Total Sleep Time Before and After CPAP Therapy in Obstructive Sleep Apnea Patients — 29 minutes — p=<0.05

Primary: Serotype Opsonization Titers — 10.85; 12.63; 132.51; 908.23 titers

Primary: Confirmed Clinical Neuropathy (CCN) — 14; 18 participants

Primary: Mean Change From Baseline to 6-Week Endpoint on the 21-Item Hamilton Depression Rating Scale (HAMD21) Total Score — -6.18; -6.25; -6.91 units on a scale — p=0.264

Primary: Safety of Meloxicam 10 mg as Assessed by the Incidence of Adverse Events From Baseline to Week 52 or Early Termination — 406; 23; 35; 127 participants

Primary: Median Time to Progression — 7.2 months

Primary: Iowa Gambling Test — -4.2; 1.7; 3.5; 5.3 Total Raw on a scale from -100 to 100 — p=>.05